E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Systemic Lupus Erythematosus |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10042945 |
E.1.2 | Term | Systemic lupus erythematosus |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025139 |
E.1.2 | Term | Lupus erythematosus systemic |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The Primary Objective of this Clinical Trial is to evaluate the long-term safety and tolerability of BIIB059 in participants with active SLE. |
|
E.2.2 | Secondary objectives of the trial |
The Secondary Objectives of this Clinical Trial are: - to evaluate the long-term effect of BIIB059 on disease activity in participants with SLE - to evaluate the long-term effect of BIIB059 in participants with SLE in maintaining low disease activity - to evaluate the effect of BIIB059 in participants with active SLE in preventing irreversible organ damage - to assess long-term use of OCS6 with participants receiving BIIB059 treatment - to assess the impact of BIIB059 on participant-reported HRQoL, symptoms and impacts of SLE - to evaluate long-term effect of BIIB059 on laboratory parameters - to evaluate immunogenicity of BIIB059
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Key Inclusion Criteria: 1. Participants who completed 1 of the 52-week of the double-blind placebo-controlled, parent Phase 3 studies (230LE303 and 230LE304) on study treatments with either BIIB059 or placebo to Week 48 and attended the last study assessment visit at Week 52. 2. Ability of the participant and/or his/her legally authorized representative (e.g., parent, spouse, or legal guardian), as appropriate and applicable, to understand the purpose and risks of the study, to provide informed consent, and to authorize the use of confidential health information in accordance with national and local privacy regulations. 3. All women of childbearing potential must agree to practice effective contraception during the study and for 126 days (18 weeks) after their last dose of study treatment. In addition, participants should not donate eggs during the study and for at least 126 days (18 weeks) after their last dose of study treatment. Where applicable, if not previously confirmed in the parent Phase 3 study, postmenopausal status must be confirmed as follows: for women ≤ 55 years of age, 52 continuous weeks of natural (spontaneous) amenorrhea without an alternative medical cause and a serum FSH level ≥ 40 mIU/mL; for women > 55 years of age, 52 continuous weeks of natural (spontaneous) amenorrhea without an alternative medical cause and a serum FSH level ≥ 40 mIU/mL, or at least 5 continuous years of natural (spontaneous) amenorrhea without an alternative medical cause. |
|
E.4 | Principal exclusion criteria |
Key Exclusion Criteria: 1. Early parent Phase 3 studies treatment terminators (participants who discontinued study treatment before Week 52). 2. Early parent Phase 3 studies terminators (participants who withdrew from study participation and did not complete the 52-week treatment period). 3. Participants who have developed any other medical diseases, conditions, or abnormalities, rendering their participation in the LTE study unsuitable in the opinion of the Investigator. 4. Participants who developed moderate-to-severe worsening of organ-specific lupus manifestations that would require a change in immunosuppressive therapy. 5. Use of prohibited concurrent medication or therapy during the parent Phase 3 studies. 6. Immunization with live or live-attenuated vaccines within 4 weeks prior to Baseline Visit. 7. Use of other investigational drugs or off-label drugs used to treat SLE, cutaneous lupus, or lupus nephritis during the parent Phase 3 studies. 8. Female participants who are pregnant, currently breastfeeding, or planning to become pregnant during the study and for 126 days (18 weeks) after the last dose of study treatment. 9. Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered (participation in observational registries is allowed). 10. Inability to comply with study requirements. 11. Other unspecified reasons that, in the opinion of the Investigator or Sponsor, make the participant unsuitable for enrollment. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary Endpoints: Incidence of TEAEs - Number of Participants with Treatment Emergent Adverse Events (TEAEs) up to Week 180
Incidence of SAEs - Number of Participants with Serious Adverse Events (SAEs) up to Week 180 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
All endpoints measured within TimeFrame as mentioned in point E.5.1 Primary end point(s) |
|
E.5.2 | Secondary end point(s) |
Secondary Endpoints: - Percentage of Participants who Achieved an Systemic Lupus Erythematosus Responder Index (SRI)-4 Response up to Week 180 - Percentage of Participants who Achieved a Joint-50 Response up to Week 180 - Percentage of Participants who Achieved Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)-50, CLASI-70, and CLASI-90 Response up to Week 180 - Percentage of Participants who Achieved a British Isles Lupus Assessment Group based Composite Lupus Assessment (BICLA) Response up to Week 180 - Annualized Severe Safety of Estrogens in Systemic Lupus Erythematosus National Assessment - Systemic Lupus Erythematosus Disease Activity Index Flare Index (SFI) Flare Rate up to Week 156 - Percentage of Time Spent in Lupus Low Disease Activity State (LLDAS) up to Week 180 - Duration of Sustained LLDAS as Defined by the Number of Visits in LLDAS up to Week 180 - Annual Change From Baseline Value From the Parent Phase 3 Studies in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) Score up to Week 156 - Cumulative Exposure to OCS Over Time up to Week 156 - Percentage of Participants With OCS ≤7.5 mg up to Week 156 - Percentage of Participants With OCS ≤5 mg up to Week 156 - Change From Baseline in Lupus-Specific Health-Related Quality-Of-Life (LupusQoL) Score up to Week 156 - Change From Baseline in Short Form Health Survey-36 (SF-36) (Acute Version) Score up to Week 156 - Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score up to Week 156 - Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Score up to Week 156 - Change From Baseline in Work Productivity and Activity Impairment (WPAI):Lupus Score up to Week 156 - Change from Baseline in Patient Global Assessment (PtGA) Score up to Week 156 - Number of Participants with Clinically Relevant Abnormalities in Standard Laboratory Parameters up to Week 180 - Number of Participants with Clinically Relevant Abnormalities in Electrocardiogram (ECGs) Results up to Week 156 - Number of Participants with Antibodies to BIIB059 up to Week 180
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
All endpoints measured within TimeFrame as mentioned in point E.5.2 Secondary end point(s) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
long-term tolerability long-term effect on disease activity |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 70 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Brazil |
Canada |
Chile |
China |
Israel |
Japan |
Korea, Republic of |
Mexico |
Peru |
Philippines |
Taiwan |
United States |
France |
Poland |
Sweden |
Bulgaria |
Netherlands |
Romania |
Spain |
Czechia |
Germany |
Greece |
Italy |
Belgium |
Hungary |
United Kingdom |
Serbia |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The EOS is the last visit for the last participant for the final collection of data for the primary outcome. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 14 |
E.8.9.2 | In all countries concerned by the trial years | 7 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |